Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Giovanni Rotondo – page 10

159 clinical trials in San Giovanni Rotondo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Giovanni Rotondo at a glance
159
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

159 trials in San Giovanni Rotondo

Open in trial search

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Golimumab for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Golimumab
  • Sponsor:Janssen Biologics B.V.

Crohn's disease

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ciprofloxacin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Cholangitis sclerosing

Not recruiting

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Polycythaemia vera+10

Not recruiting

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Panobinostat
  • Sponsor:Novartis Pharma Services AG

Colorectal cancer metastatic

Not recruiting

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Fondazione GONO G.I.

Acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in San Giovanni Rotondo

What the registry says about research in the country

01 Gastrointestinal Oncology

Clinical research focusing on metastatic colorectal cancer and gastroesophageal cancers, evaluating novel combination therapies and targeted treatments.

  • Advanced colorectal cancer treatments
  • HER2-positive gastric cancer therapies
  • Targeted molecular therapies
02 Inflammatory Bowel Disease

Studies examining innovative treatments for Crohn's Disease and Ulcerative Colitis, testing new therapeutic combinations and treatment strategies.

  • Novel biological therapies
  • Combination treatment approaches
  • Disease remission strategies
03 Hematologic Malignancies

Research initiatives in acute myeloid leukemia, multiple myeloma, and other blood cancers, exploring innovative therapeutic approaches.

  • Targeted leukemia treatments
  • Novel drug combinations
  • Immunotherapy approaches
04 Breast and Urological Cancers

Investigations into early breast cancer treatments and therapies for prostate cancer, with focus on hormone-responsive diseases.

  • Endocrine therapy optimization
  • Advanced prostate cancer treatments
  • Targeted therapeutic approaches
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.